Researchers from the Ocean University of China described XZ-8078, a new dual-target protein degrader that simultaneously targets PARP1 and IKZF3, offering a potential strategy to enhance antitumor activity through coordinated pathway inhibition.

Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer.

Hinova Pharmaceuticals Inc. has patented new molecular glue degraders comprising E3 ubiquitin-protein ligase binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. As such, they are reported to be potentially useful for the treatment of autoimmune diseases, inflammatory disorders and cancer.

Gan & Lee Pharmaceuticals Co. Ltd. has divulged new molecular glue degraders comprising cereblon (CRBN)-binding agents and casein kinase 1 isoform α (CK1α, CSNK1A1) degradation moieties potentially useful for the treatment of cancer.

Merck KGaA has discovered new GTPase KRAS mutant degradation inducers potentially useful for the treatment of cancer.

Shenzhen Linggene Biotechnology Co. Ltd. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase (OGT)-targeting moiety acting as OGT degradation inducers.

Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer.

Nurix Therapeutics Inc. has disclosed new proteolysis targeting chimera (PROTAC) compounds potentially useful for the treatment of cancer.